UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See

Instruction 1(b).

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E. 42ND STREET

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol

AQUINOX PHARMACEUTICALS, INC

[ AQXP ]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director

10% Owner

Officer (give title below)

Other (specify below)

3. Date of Earliest Transaction

(Month/Day/Year)

03/12/2014

4. If Amendment, Date of Original Filed

(Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr.

3)

2. Transaction Date

(Month/Day/Year)

2A. Deemed Execution Date, if any

(Month/Day/Year)

3. Transaction Code (Instr.

8)

4. Securities Acquired (A) or Disposed Of (D) (Instr.

3, 4 and 5)

5.

Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.

3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

7. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

Amount

(A) or (D)

Price

Common Stock

03/12/2014

962,603

(1)

962,603

Common Stock

03/12/2014

272,727

$11

1,235,330

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.

3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date

(Month/Day/Year)

3A. Deemed Execution Date, if any

(Month/Day/Year)

4. Transaction Code (Instr.

8)

5.

Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.

3, 4 and 5)

6. Date Exercisable and Expiration Date

(Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr.

3 and 4)

8. Price of Derivative Security (Instr.

5)

9.

Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.

4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

11. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Series B-1 Preferred Stock

(1)

03/12/2014

334,420

(1)

(1)

Common Stock

334,420

(1)

Series B-2 Preferred Stock

(1)

03/12/2014

327,178

(1)

(1)

Common Stock

327,178

(1)

Series C Preferred Stock

(1)

03/12/2014

301,005

(1)

(1)

Common Stock

301,005

(1)

Explanation of Responses:

1. Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date.

Remarks:

/s/ Susan Grant, Assistant Secretary on behalf of Pfizer Inc.

03/14/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,

see

Instruction

(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations

See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,

see

Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.